SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Non-Tech : adnews
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: KevRupert who started this subject3/7/2001 7:14:24 AM
From: KevRupert   of 252
 
Genentech (DNA-$52.20) AAD Meeting:

DNA: XANELIM LOOKING GOOD -- POSITIVE RESULTS FROM THE 2001 AAD MEETING

DNA
RATING STRONG BUY
TARGET $110.00

Promising Phase II Xanelim results were highlighted at the 2001 meeting of the American Academy of Dermatology (AAD).
75% of patients in a Phase II study experienced a 50% or better improvement as measured by the PASI (psoriasis area and severity index) score, while 31% of patients improved at least 75% from baseline.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News